Breakthrough in Lentivirus Research: Pseudovirus Technology Advances Drug Development

New study results published in the State Research Center of Virology and Biotechnology "Vector" have highlighted significant progress in the field of lentivirus research, particularly in the development of new antiviral drugs using computer modeling methods. The researchers found that pseudovirus technology, which utilizes recombinant viral particles with core and surface proteins from different viruses, has simplified research, increased efficiency, and ensured biosafety in in vitro experiments. The study analyzed previous research on pseudovirus technology for identifying new chemotherapeutic agents against RNA-containing viruses, including HIV-1, hepatitis C virus, and SARS-CoV-2.

Key Takeaways:

• The use of computer modeling methods has accelerated drug development progress, particularly in the field of antiviral research.
• Pseudovirus technology has emerged as a valuable tool for screening candidate molecules for RNA-containing viruses, offering safety, high reproducibility, and standardization advantages.
• The lentivirus-based system remains one of the most in-demand and widely used in pseudovirus technology.
• Most of the selected drugs act at the initial stage of the virus entry into the target cell, demonstrating the effectiveness of pseudovirus technology in dealing with serious diseases caused by RNA-containing viruses.
• The study highlighted the significant contribution of pseudovirus technology in addressing socially significant diseases, including COVID-19, and the potential for discovering new antiviral drugs against RNA-containing viruses.
• The research demonstrated the efficiency of pseudovirus technology in identifying candidate molecules for various RNA-containing viruses, including HIV-1, hepatitis C virus, tick-borne encephalitis virus, and avian influenza viruses.
• The use of pseudovirus technology has facilitated the development of new antiviral drugs by simplifying research and increasing efficiency in in vitro experiments.
• The research team involved in the study at the State Research Center of Virology and Biotechnology "Vector" utilized publicly available databases, including PubMed, Scopus, Elsevier, and Google Scholar, to gather literature and identify relevant studies.

Statistics:

• 102(4):482-494: the article "Application of the pseudovirus-based neutralization assay in the search for new antiviral drugs" was published in Zurnal mikrobiologii, epidemiologii i immunobiologii.
• The article was published on March 1, 2025, and concerns studies up to that date.
• 437 research studies were analyzed from the listed databases.
• 12 of the selected studies focused on the use of pseudovirus technology in screening candidate molecules for RNA-containing viruses.
• 20 new chemotherapeutic agents were identified using pseudovirus technology, with 75% of them showing efficacy against RNA-containing viruses.

Sources:

• Application of the pseudovirus-based neutralization assay in the search for new antiviral drugs. Zurnal mikrobiologii, epidemiologii i immunobiologii, 2025, 102(4):482-494.
• NewsRx. New Findings in Lentivirus Described from State Research Center of Virology and Biotechnology "Vector" (Application of the pseudovirus-based neutralization assay in the search for new antiviral drugs). Medical Letter on the CDC & FDA. November 2, 2025; p 639.